Peptide News Digest

#Melflufen (Pepaxti)

3 stories

Melflufen is a peptide-drug conjugate from the Swedish company Oncopeptides: a short peptide linked to a chemotherapy payload that is released inside cells. Sold as Pepaxti with dexamethasone, it is approved in the European Union and the UK for multiple myeloma that has stopped responding to three main drug classes.

Its regulatory paths have split. The FDA withdrew the U.S. approval, under the name Pepaxto, on February 23, 2024, after the OCEAN trial did not confirm a clinical benefit. In Europe, the CHMP recommended on September 17, 2026 moving Pepaxti to earlier, third-line use.

Oncopeptides is also testing whether melflufen can reach brain tumors. In October 2026 it reported finding the drug in tumor tissue removed from the first three glioblastoma patients in its small INSULA study, a test of delivery rather than benefit.

See #oncopeptides, #peptide-drug-conjugate, and #glioblastoma.

Clinical Trials · View digest

Oncopeptides Says Its Peptide-Drug Conjugate Melflufen Reached Brain Tumor Tissue in the First Three Glioblastoma Surgery Patients

Oncopeptides reported on October 9, 2026 that in the open-label INSULA window-of-opportunity study at Oslo University Hospital, active drug was found in resected tumor tissue from the first three patients with recurrent glioblastoma given melflufen, its EMA-approved peptide-drug conjugate, before surgery, meeting the study's primary goal of showing the drug crosses the blood-brain barrier. The company said tumor drug levels matched what animal studies predicted but gave no numbers, and the study is not designed to show clinical benefit. It plans to enroll about 10 patients and will discuss the data in an investor webcast on October 12.

Regulatory · View digest

CHMP Recommends Moving Oncopeptides' Pepaxti (Melflufen) Peptide-Drug Conjugate to Third-Line Multiple Myeloma in the EU

Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.

Regulatory · View digest

Oncopeptides Plans EMA Type II Variation to Expand Pepaxti (Melflufen) Peptide-Drug Conjugate Label to Third-Line Multiple Myeloma

Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.